Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD

We read with great interest the Delphi consensus statement regarding the change in the nomenclature of fatty liver disease to "steatotic liver disease" (SLD).1 The debate on the nomenclature of non-alcoholic fatty liver disease (NAFLD) was sparked by a group of experts who suggested renaming NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD).2 In a nutshell, any patient with fatty liver who is obese or has type 2 diabetes mellitus (T2DM) or fulfils two out of seven metabolic risk factors namely central obesity, hypertension, pre-diabetes, hypertriglyceridemia, low HDL, elevated high-sensitivity C-reactive protein (hs-CRP) or insulin resistance (as assessed by HOMA-IR) was classified as having MAFLD.